US Oncology Ecosystem
	CARE DELIVERY (Providers)
		NCI Comprehensive Cancer Centers
			MD Anderson
			Memorial Sloan Kettering
			Dana-Farber
			Fred Hutch
			Moffitt
			City of Hope
			Role: Research + clinical, trials, complex cases
			~72 NCI-designated (53 comprehensive)
			⭐ RISA: Complex claim adjudication, denial mgmt for novel therapies
		Academic Medical Centers
			Stanford Cancer Center
			UCSF
			Johns Hopkins
			Mayo Clinic
			Cleveland Clinic
			Role: Teaching + research + tertiary referrals
			⭐ RISA: Multi-dept charge capture, referral auth automation
		Community Oncology Practices ⭐ PRIMARY TARGET
			Texas Oncology (550+ docs, 250+ sites)
			Florida Cancer Specialists
			Regional Cancer Care Associates
			Oncology Hematology Care
			Delivers 60%+ of US cancer care
			Ownership: Physician-owned / PE-backed / Health system
			Pain: Margin pressure, denials, staffing, pathway compliance
			⭐ RISA: Prior auth, denial prevention, buy-and-bill, coding
		Hospital System Cancer Programs
			HCA Healthcare
			Providence
			Intermountain
			Northwell
			CommonSpirit
			Atrium Health
			Role: Integrated delivery, employed oncologists
			⭐ RISA: Service line revenue integrity, 340B compliance
		Oncology Networks / Management Orgs
			US Oncology Network (McKesson) — 1,400+ physicians
			OneOncology (TPG) — 600+ providers, PE-backed
			American Oncology Network (AON) — physician-led
			Flatiron Health (Roche) — EHR + RWD platform
			Role: GPO, practice mgmt, pathways, data aggregation
			⭐ RISA: Platform-level RCM (1 integration → 100s of practices)
	PAYERS & REIMBURSEMENT
		Medicare / CMS
			Medicare FFS — pays per service
			Medicare Advantage — ~52% of beneficiaries, managed care
			Enhancing Oncology Model (EOM) — episode-based payments
			Largest single oncology payer (median age 66)
			⭐ RISA: Denial reduction, EOM reporting, MA prior auth
		Commercial Payers
			UnitedHealthcare (owns Optum)
			Elevance Health (Anthem/BCBS)
			Aetna (CVS Health)
			Cigna (owns Express Scripts)
			Blue Cross Blue Shield (34 independents)
			Mechanisms: Prior auth, step therapy, pathways, site-of-care
			⭐ RISA: Prior auth automation, claims accuracy, pathway docs
		Medicaid
			50 state programs + DC
			Managed Medicaid dominant
			Low reimbursement, complex eligibility
			⭐ RISA: Eligibility verification, dual-eligible coordination
		Specialty Pharmacy / PBMs
			CVS Caremark (#1 PBM)
			Express Scripts / Cigna (#2)
			Optum Rx / UHG (#3)
			Magellan Rx — oncology specialty
			Role: Oral oncolytics (~40% of pipeline), formulary mgmt
			⭐ RISA: Oral oncolytic prior auth, benefits investigation
		Value-Based Care Programs
			EOM (successor to OCM) — CMS episode payments
			Clinical Pathways: Via Oncology, NCCN, Elsevier
			Bundled Payments
			⭐ RISA: EOM tracking, pathway adherence, episode analytics
	PHARMA & BIOTECH
		Large Pharma Oncology (~$220B+ global)
			Merck — Keytruda ($25B, #1 drug globally)
			Roche/Genentech — Tecentriq, Herceptin, Foundation Medicine
			BMS — Opdivo, Revlimid, Abecma (CAR-T)
			AstraZeneca — Tagrisso, Enhertu
			Pfizer — Ibrance, Seagen (ADCs), Padcev
			Novartis — Kisqali, Kymriah (CAR-T), Pluvicto
			Eli Lilly — Verzenio, Retevmo
			J&J — Darzalex, Carvykti (CAR-T)
			AbbVie — Imbruvica, Venclexta
		Emerging Biotech
			CAR-T: Kite/Gilead, Novartis, BMS, Legend/J&J ($300-500K/treatment)
			ADCs: Seagen/Pfizer, Daiichi Sankyo/AZ, Gilead
			Bispecifics: Amgen, Roche, AbbVie
			Radiopharmaceuticals: Novartis, Point Bio, RayzeBio/BMS
			⭐ RISA: Novel therapy billing, J-code mgmt, pass-through tracking
		Biosimilars
			Sandoz, Amgen, Teva, Coherus, Fresenius Kabi
			Disrupting reference biologics (15-40% savings)
			⭐ RISA: Biosimilar vs reference billing accuracy
		Specialty Distributors (Big 3)
			McKesson (#1 + US Oncology + GPO)
			Cencora / AmerisourceBergen (#2)
			Cardinal Health (#3 + nuclear pharmacy)
			Role: Drug distribution, buy-and-bill logistics
			⭐ RISA: Inventory-to-billing reconciliation, waste billing (JW)
	DIAGNOSTICS & PRECISION MEDICINE
		Genomic Testing / CDx
			Foundation Medicine (Roche) — FoundationOne CDx
			Tempus — xT, xF panels + AI insights
			Guardant Health — Guardant360, Shield (screening)
			Myriad — BRACAnalysis, myChoice
			NeoGenomics — specialty cancer testing
			Natera — Signatera (MRD monitoring)
			⭐ RISA: Genomic test prior auth, LCD/NCD matching, ABN generation
		Pathology / Lab
			Quest Diagnostics
			Labcorp (+ Invitae)
			Hospital-based pathology
			Pain: Pathologist shortage, digitization
		Imaging
			Radiology Partners, RadNet, SimonMed
			PET/CT centers — critical for staging
			Pain: Prior auth burden for PET/CT
			⭐ RISA: Imaging prior auth, appropriate use criteria
		AI Diagnostics
			Paige AI — FDA-cleared pathology AI
			Lunit — radiology + pathology
			PathAI — biopharma pathology partnerships
	CLINICAL TRIALS & RESEARCH
		NCI / NIH (~$7B annual budget)
			SWOG, ECOG-ACRIN, Alliance, NRG Oncology, COG
			⭐ RISA: Trial billing compliance (qualifying vs routine costs)
		CROs
			IQVIA (largest)
			PPD / Thermo Fisher
			Parexel
			Syneos Health
		Decentralized Trial Platforms
			Medidata (Dassault) — Rave
			Veeva Systems — Vault CTMS
			Science 37 — virtual trials
		Trial Matching
			Tempus — AI-driven from genomic + clinical
			TrialJectory — patient-facing
			Massive Bio — community oncology
		Real-World Data / Evidence
			Flatiron Health (Roche) — 280+ clinics, gold standard
			Tempus — multimodal (genomic + clinical + imaging)
			ASCO CancerLinQ
			Optum Labs, Komodo Health
			⭐ RISA: Claims data enrichment for better RWE
		Philanthropic Accelerators
			Parker Institute (PICI) — immunotherapy, $250M Sean Parker
			Stand Up to Cancer — Dream Teams
			V Foundation
			LLS — blood cancer research + patient support
	TECHNOLOGY & DATA
		Oncology EHRs
			Flatiron OncoEMR — community practices
			Varian ARIA — radiation oncology
			Elekta MOSAIQ — radiation oncology
			iKnowMed (McKesson) — US Oncology network
			Epic Beacon — oncology module
			⭐ RISA: EHR integration for automated charge capture
		General EHRs
			Epic — dominant in large systems
			Oracle Health (Cerner) — #2
			⭐ RISA: FHIR API integration for clinical→billing bridge
		RCM / Billing ⭐⭐ CORE MARKET
			Waystar — claims, prior auth (IPO 2024)
			Availity — payer connectivity
			Change Healthcare (Optum) — ~50% of US claims
			R1 RCM — end-to-end outsourcing
			Coronis Health — specialty RCM
			Pain: 10-15%+ denial rates, 2-14 day prior auth delays
			⭐ RISA: Denial prevention, prior auth, coding, underpayment detection
		AI Companies in Oncology
			Clinical AI: Tempus, Flatiron, Paige, Lunit, PathAI
			RCM AI: RISA Labs ⭐, Waystar AI, Akasa, Infinx
			Patient Access AI: Notable Health, Qventus, Cedar
			Olive AI (shut down 2023) — cautionary tale
		Radiation Oncology Tech
			Varian/Siemens — linacs, ARIA, Ethos
			Elekta — linacs, Unity MR-Linac, MOSAIQ
			Accuray — CyberKnife, TomoTherapy
			⭐ RISA: Rad onc billing (most complex in medicine)
		Data Aggregators
			Definitive Healthcare
			IQVIA
			Komodo Health
			Symphony Health, Truveta
	REGULATORS & GUIDELINES
		FDA
			Drug approvals, breakthrough designations
			RTOR (Real-Time Oncology Review), Project Orbis
			Impact: New approvals → new billing codes
		CMS
			Coverage determinations (NCD/LCD)
			Payment models: OPPS, PFS, IPPS, EOM, RO Model
			Quality: MIPS, APMs
			⭐ CMS rules = billing complexity driver
		NCCN
			Gold-standard treatment guidelines
			Compendia listing drives off-label coverage
			Basis for medical necessity / appeals
		ASCO / ESMO
			ASCO: QOPI certification, CancerLinQ, guidelines
			ESMO: European counterpart
		State Regulators
			Certificate of Need laws
			Oral parity laws (43+ states)
			Scope of practice, pharmacy compounding
		Accreditation
			Commission on Cancer (CoC/ACS)
			QOPI Certification (ASCO)
			ACR — imaging centers
			FACT — cellular therapy (CAR-T)
	PATIENTS & ADVOCACY
		Patient Advocacy Orgs
			American Cancer Society (largest)
			Leukemia & Lymphoma Society
			Susan G. Komen — breast
			PanCAN — pancreatic
			LUNGevity — lung
			Colorectal Cancer Alliance
			Prostate Cancer Foundation
		Patient Navigation
			Nurse navigators (CoC requirement)
			Social workers
			Financial counselors
			⭐ RISA: Automated financial counseling, benefits verification
		Patient Support Programs
			Manufacturer copay assistance
			Foundations: PAN, HealthWell, CancerCare, NeedyMeds
			Free drug / PAP programs
			⭐ RISA: PSP enrollment automation, copay accumulator tracking
		Survivorship
			~18M cancer survivors in US
			Long-term follow-up, late effects, surveillance
	FINANCIAL / INVESTMENT
		Private Equity in Oncology
			TPG Capital — OneOncology
			Webster Equity Partners
			General Atlantic
			GenStar Capital
			Trend: Aggressive consolidation 2020-2025
			⭐ PE platforms = sophisticated tech buyers
		Venture Capital
			Tempus ($6.1B at IPO)
			Guardant ($3B+ market cap)
			Shift: Hype → proof of ROI
		Public Markets
			Tempus AI (TEM) — genomics + AI
			Guardant Health (GH) — liquid biopsy
			Exact Sciences (EXAS) — Cologuard, Oncotype
			Natera (NTRA) — Signatera MRD
			Waystar (WAY) — RCM tech
	KEY FLOWS
		Money: Patient→Provider (copay), Payer→Provider (reimbursement), Provider→Distributor→Pharma (drugs)
		Money: Pharma→Payer (rebates), Pharma→CRO→Provider (trial funding), PE/VC→Practices/Tech
		Data: Provider→Clearinghouse→Payer (claims), Provider→EHR→Aggregator (clinical)
		Data: Diagnostics→Provider (genomic reports), Payer→Provider (auth decisions, ERA)
		Data: Aggregator→Pharma (de-identified RWD), NCCN/FDA/CMS→All (guidelines, policies)
		Prior Auth Flow: Identify need → Check policy → Submit auth → Payer reviews → Approve/Deny → Appeal → Treat → Claim → Adjudicate
		Buy-and-Bill: Purchase drug → Administer → Bill J-code + admin CPT → Reimburse ASP+6% → Margin = Reimburse−Cost
		⭐ RISA intervenes: Policy check, auth submission, appeal, coding, claim, adjudication
